Medicamen Biotec (MEDICAMEQ)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At ₹259, Medicamen Biotec is no compounder. Mr Market prices it at 46 times earnings, but the business has grown sales only 5.71% and profits 2.78%. That gives a PEG of 10.89—whatever growth exists is already more than paid for. Graham would ask: what am I getting? Book value ₹164 gives P/B 1.58, not extreme, but return on that book is just 4.01%; ROCE is 6.77%. A business earning 4% on equity is not creating much value for shareholders, especially after inflation. The balance sheet is reasonable—D/E 0.14, and Piotroski F-Score 7/9 hints at decent financial health. But a low-debt, mediocre-return pharma company is not a wonderful business at a fair price; it is a fair business at a demanding price. The latest quarter, ₹43 Cr sales and ₹3 Cr profit, confirms small scale. With promoter holding at 40.46%, I need to see whether they are buyers or sellers. Dividend yield of 0.33% means income seekers need not apply. The 52-week range of ₹216 to ₹447.65 shows the shares have fallen hard; Mr Market has soured. That is good—it creates a potential entry if fundamentals improve. But I do not just buy falling prices; I buy value. At 46 times earnings and single-digit growth, there is no margin of safety. If the business matures and growth stays below 5%, the earnings yield of roughly 2.2% cannot justify the risk. For an Indian retail investor, patience is key. Watch whether sales and profit growth accelerate, whether ROE climbs towards 12-15%, and whether the company uses its low debt to expand profitably. Until then, this goes on the watchlist, not the shopping list.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer